Medtronic PLC $MDT Shares Acquired by Twin Capital Management Inc.

Twin Capital Management Inc. lifted its position in shares of Medtronic PLC (NYSE:MDT) by 41.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,306 shares of the medical technology company’s stock after purchasing an additional 10,311 shares during the period. Twin Capital Management Inc.’s holdings in Medtronic were worth $3,363,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. AXQ Capital LP raised its position in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after acquiring an additional 2,013 shares in the last quarter. UMB Bank n.a. increased its stake in Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the last quarter. Principal Financial Group Inc. increased its stake in Medtronic by 17.2% in the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after purchasing an additional 242,910 shares during the last quarter. Sector Gamma AS raised its holdings in Medtronic by 35.5% during the third quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock worth $28,900,000 after purchasing an additional 79,441 shares in the last quarter. Finally, Verdence Capital Advisors LLC lifted its position in shares of Medtronic by 22.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after buying an additional 5,296 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of recent analyst reports. Daiwa Securities Group increased their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Barclays upped their price objective on shares of Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research note on Thursday, January 8th. Robert W. Baird set a $103.00 target price on Medtronic in a research report on Tuesday, December 16th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.67.

Medtronic Stock Performance

NYSE:MDT opened at $102.89 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market cap of $131.91 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71. The firm’s fifty day moving average price is $99.40 and its 200 day moving average price is $96.10. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the business earned $1.26 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).